Group items tagged

Patient safety should remain a top priority in any healthcare setting. People should always receive the right advice, and pharmacists aren't 'GPs on the cheap.' Staff should be fully trained, and medical equipment should be correctly maintained at all times. In turn, this helps create a safer environment for patients and professionals alike. In this article, we'll discuss some of the factors that can enhance patient safety in healthcare settings. AUTOMATION AND MONITORING Automating processes within a facility can help streamline operations. This has the potential to reduce or eliminate human error that could result in serious injury or death. In addition, automated systems often provide instant alerts when something goes wrong - allowing medical staff to react quickly and appropriately. Automated solutions can help facilities achieve hand hygiene monitoring standards, and it's possible to schedule a demo and see their outcomes. They can reduce staff sick time and HAIs, as well as Joint Commission citations and associated costs. Monitoring helps ensure compliance with safety protocols. It's essential for improving patient safety and gaining data on all aspects of a facility's operations. It also helps organizations track the effectiveness of their protocols and procedures over time. This helps them constantly evaluate and refine their policies, to maximize patient safety benefits. ADEQUATE STAFFING In order to provide quality care, it's essential to have enough staff on hand to meet patient needs and ensure all protocols are being followed. Without this, healthcare providers may struggle to provide prompt, efficient care - which can put patient safety at risk. Adequate staffing levels should be determined by a variety of factors. They include patient numbers, the complexity of care required, and the size and layout of the facility.

Following concerns raised about cracked cartridges and insulin leaks, the Medicines and Healthcare products Regulatory Agency (MHRA) has issued a national patient safety alert for the NovoRapid PumpCart prefilled insulin cartridge and the Roche Accu-Chek Insight Insulin pump system. The regulator have asked patients to check the pre-filled glass insulin cartridge for cracks before use. It advised against using the cartridge if it has been dropped even if no cracks are visible and urged to closely follow the updated handling instructions in the pump user manual when changing pre-filled glass insulin cartridges. In some of the reported leakage incidents, the cartridges were found to be cracked and provided an inadequate supply of insulin to patients. Leakages also occurred in cases where no cracks in the cartridge were visible, the regulator said. In some patients there were consequences of not receiving enough insulin from their pump system, including reports of severely high blood sugar and diabetic ketoacidosis, a serious complication of diabetes when the body produces high levels of blood acids called ketones. Healthcare professionals are being advised to contact patients over the next six months using said device to discuss their individual needs and source an alternative pump where appropriate. "Because of the rare risk of insulin leakage from the Roche Accu-Chek Insight Insulin Pump, patients should check the pre-filled glass insulin cartridge for any cracks prior to usage," Dr June Raine, MHRA chief executive, said.

Three batches of Mexiletine hydrochloride 50mg, 100mg and 200 mg hard capsules manufactured by Clinigen Healthcare has been recalled. Pharmacists are urged to quarantine the said batches and return it to the supplier by or before 12 August. Clinigen Healthcare Ltd has initiated a recall of three batches of Mexiletine hydrochloride hard capsules due to a potential risk of under dose or overdose, which could have consequences for the safety of patients. The manufacturer has confirmed that no alternative batches of Mexiletine hydrochloride 50mg, 100mg or 200mg hard capsules will be available until later in the year, therefore the recall of these batches from patients should only be considered where patients have access to appropriate alternative products. See below for more information on resupplying patients with alternative products. "Patients should be advised not to stop any treatments without consulting their relevant healthcare professional. The risks of suddenly stopping medication for ventricular arrhythmias is higher than the potential risk presented by too much or too little of the active ingredient in the capsule."

The Department of Health and Social Care (DHSC), led by Victoria Atkins MP and Maria Caulfield MP, has unveiled proposed updates to the NHS Constitution for England, aiming to fortify the principles of privacy, dignity, and safety for all patients. Martha's rule was prompted by a campaign led by the parents of 13-year-old Martha Mills who tragically succumbed to sepsis after staff at King's College Hospital failed to escalate her care to intensive care, despite her family's pleas regarding her worsening condition in 2021. Under the new guidance is the introduction of Martha's Rule, empowering patients to request intimate care from someone of the same biological sex ensuring that the distinct needs of men and women are recognized and addressed. Patients and their loved ones can exercise the right to "access to a rapid review from outside the care team if the patient is deteriorating." The consultation on the proposed updates is set to run for eight weeks, inviting feedback from patients, healthcare professionals, and stakeholders for a review

Travelling with medical cannabis can be a complex and often confusing experience, given the diverse legal regulations across different countries and states. Patients who rely on medical cannabis for their wellbeing need to be well-informed and prepared to ensure a smooth and hassle-free travel experience. This comprehensive guide covers essential aspects, legal considerations, and practical tips for individuals who use medical cannabis and wish to travel. Know the Laws The first and most crucial step before travelling with medical cannabis is to understand the laws and regulations of both the departure and destination locations. Laws regarding medical cannabis use vary significantly from one country, state, or even city to another. Some places have legalised medical cannabis, while others strictly prohibit its use. Researching and familiarising oneself with the specific regulations of the destination, transit countries, and the home country is essential. Travelling Within the Same Country When travelling within a country where medical cannabis is legal, patients generally need to carry their prescription information issued by a licensed healthcare provider. It's advisable to keep medical cannabis in its original packaging, clearly labelled with the patient's name, prescribing physician, and dosage instructions. Carrying a copy of the relevant laws and regulations can also be helpful in case of any inquiries from authorities. What can be easier than carrying around paperwork, which could get easily damaged or lost during your travels, is to get a medical card that has a unique QR code on it from Releaf Cannabis, which, when scanned, can present their prescription information digitally - it has revolutionised the way patients manage their healthcare. This eliminates the need for physical documents and streamlines the process but also ensures the security and confidentiality of sensitive medical information, offering patients a more efficient and organi

Pharmacy professionals to be included as key stakeholders in the implementation, delivery and evaluation of a wide range of genomic services, said the Royal Pharmaceutical Society (RPS). RPS's statement has been developed in collaboration with pharmacy organisations who have co-badged the report, such as the British Oncology Pharmacy Association, the UK Clinical Pharmacy Association, Association of Pharmacy Technicians and the College of Mental Health Pharmacy. It looks at current and future roles for pharmacy professionals in genomic medicine across many aspects of practice such as person-centred care and collaboration, professional practice, education, leadership, management and research. Pharmacists and pharmacy technicians in the UK have already established roles in the application of genomic medicine in some areas of practice, such as antimicrobial stewardship and infectious diseases, and the management of certain genetic conditions, such as cystic fibrosis. The society believes, the current role of pharmacy professionals in genomics can be expanded upon in the future to both lead and support many relevant aspects of genomic implementation. These are described across all healthcare sectors, within the Genome UK strategy produced by the UK Government, and within the implementation plans published in England, Scotland and Wales. Lead for Pharmacogenomics at RPS Sophie Harding said: "Pharmacy professionals are the gatekeepers of medication safety and efficacy across all areas of healthcare. They are skilled at interpreting complex scientific data and use evidence-based medicine to maximise the benefits of treatments for patients, whilst supporting shared decision-making with patients and the multidisciplinary team.

Errors of any kind in medical settings can have dire consequences for patients and healthcare systems. Unfortunately, negligence, misdiagnosis, and medication errors aren't uncommon in the UK. In this article, we discuss the nature of medication errors in the NHS, outline potential causes, and delve into how and why technology could be turning the tide on the issue. Prevalence and consequences of medication errors Medication errors are incidents involved with the administering, prescribing, dispensing or monitoring of medicine to patients. It can happen at many different steps in the healthcare process and by any medical professional in the system. Many cases are avoidable. According to analysis from BMJ, there are an estimated 237 million medication errors made in England every year. The majority of these are minor errors, but 1 in 4 cases has the potential to cause moderate to serious harm to patients. Not only do these errors cost the NHS significantly, at almost £100 million every year, but there is a shocking cost to public health. Lives are being lost because of medication errors which is unforgivable and tragic for the families involved. Drains on NHS resources have widespread impacts on public health and the operations of healthcare organisations up and down the country. Individual errors and mistakes may seem inconsequential (in minor cases), but they all add up in the big picture to a significant concern for policymakers.

Britain's drug regulator, the Medicines and Healthcare products Regulatory Agency (MHRA) on Monday announced that fluoroquinolone antibiotics must only be administered when no other antibiotics are appropriate for use. It elaborated that fluoroquinolones given systemically (by mouth, injection, or inhalation) should only be prescribed "when other recommended antibiotics have failed, will not work due to resistance, or are unsafe to use in an individual patient." Previous regulations on fluoroquinolones stated that this class of antibiotics should not be prescribed for mild to moderate or self-limiting infections, or non-bacterial conditions. Further restrictions have been introduced after receiving reports from patients who have experienced long-lasting or disabling reactions following use of fluoroquinolones, the MHRA revealed. Dr Alison Cave, MHRA Chief Safety Officer, said: "Patient safety is our top priority. We have listened to the experience of patients regarding long-lasting and potentially irreversible adverse reactions following use of fluoroquinolone antibiotics, in some cases prescribed for mild-to-moderate infections.

The Association of the British Pharmaceutical Industry (ABPI) today released a new guidance to pharmaceutical companies using Disclosure UK which it said will boost transparency in the relationships between healthcare professionals, other relevant decision-makers and the industry. The guidance encourages companies to use 'Legitimate Interests' as their lawful basis for processing individual's data, in order to increase the number of named healthcare professionals and other individuals on Disclosure UK, the database showing the payments and benefits in kind made by the pharmaceutical industry to doctors,nurses and other health professionals and organizations. "I'm pleased the ABPI is launching this new guidance which will boost patient safety and public confidence in our healthcare professionals," Patient Safety and Primary Care Minister Maria Caulfield commented.

The Medicines and Healthcare Products Regulatory Agency (MHRA) confirmed that Ozempic has been found at two UK wholesalers on 18 October. The pre-filled falsely labelled pens have been purchased from legitimate suppliers in Austria and Germany. However, there has been no evidence that fake Ozempic has been supplied to UK patients. Dr Alison Cave, MHRA Chief Safety Officer spoke about closely with regulatory partners to ensure patients' safety. He said: "Buying semaglutide from illegally trading online suppliers significantly increases the risk of getting a product either falsified or not licensed for use in the UK. "Products purchased in this way will not meet our strict quality and safety standards, and taking such medicines may put your health at risk," he added.

The Royal Pharmaceutical Society (RPS) Director for Scotland, Clare Morrison will be joining NHS Scotland in January. Morrison has been appointed Director of Community Engagement at Healthcare Improvement Scotland. Paul Bennett, RPS CEO said: "Many people, particularly in Scotland, will know of Clare's passion for quality improvement and patient involvement in the co-design of services. This was demonstrated through her previous work on the development of Near Me, NHS Scotland's video consulting service, and its co-design with the public, patients, clinicians and NHS staff which gained international recognition from the Institute for Healthcare Improvement. "Therefore, this is an exciting opportunity for Clare to join Healthcare Improvement Scotland to take on a strategic leadership role in supporting effective community engagement across health and social care in Scotland. It also enables Clare to make even greater use of her training as an NHS Scotland Scottish Quality & Safety Fellow and we wish her every success in her new role.

The Department of Health and Social Care (DHSC) and the Medicines and Healthcare Products Regulatory Agency (MHRA) have authorised community pharmacies throughout the UK to dispense original full packs of Valproate-containing medicines upon prescription. The necessary changes in regulations came into effect on 11 October which was strongly supported by 85 per cent of respondents concerned about risks to the unborn baby if valproate-containing medicines are used in pregnancy. The decision was made to ensure patients receive safety warnings and pictograms, including a patient card and the Patient Information Leaflet (PIL), contained in the manufacturer's original full pack. Valproate is a treatment for epilepsy and bipolar disorder but is also associated with birth defects and neurological disabilities.

The Medicines and Healthcare products Regulatory Agency (MHRA) has reminded healthcare professionals prescribing aripiprazole to alert patients about its possible side effects, following a rise in the number of reports of gambling disorder associated with the drug. Patients taking aripiprazole, which is used for the treatment of schizophrenia and bipolar disorder, are at risk of developing unusual urges or cravings that they cannot resist, including behaviours such as addictive gambling, excessive eating or spending, or an abnormally high sex drive. The regulator has received 69 reports of gambling or gambling disorder suspected to be caused by aripiprazole in the last 14 years via the Yellow Card Scheme, out of which 32 were received between 1 January and 31 August this year. Alison Cave, MHRA Chief Safety Officer, said: "The number of reports for suspected gambling and other impulsive behaviours associated with aripiprazole are small in comparison to the frequency with which it is prescribed, but the consequences for any patient developing these conditions can be significant."

Cancer patients in the UK are being given a new immunotherapy treatment at Imperial College Healthcare NHS Trust as part of a global phase 1/2 clinical trial, which aims to evaluate its safety and potential for treating 'solid tumour' cancers such as melanoma and lung cancer. The experimental therapy, called mRNA-4359, has been designed to train patients' immune systems to recognise and fight cancer cells, according to researchers at Imperial College London. For the first time in the UK, cancer patients received the treatment at the National Institute for Health and Care Research (NIHR) Imperial Clinical Research Facility at Hammersmith Hospital. In this non-randomised trial, mRNA-4359 is administered to patients either alone or in combination with an existing cancer drug called pembrolizumab, a type of immune checkpoint inhibitor. The researchers are hopeful that this new therapeutic approach, if proven to be safe and effective in clinical trials, could lead to a new treatment option for difficult-to-treat cancers.

Royal Pharmaceutical Society (RPS) and the Royal College of General Practitioners in Scotland hosted an event celebrating the collaborative work of the health professions and policy makers in Scotland on reducing the environmental harm from prescribing and medicines use. To share priorities for the Scottish Government, Alpana Mair, Head of Effective Therapeutics and Prescribing spoke and National Clinical Director Jason Leitch appeared virtually. Gillian MacKay MSP, Scottish Greens spokesperson for Health and Social Care also joined in-person. Medicines account for around 25% of the NHS's carbon emissions and have an ecological impact when they enter our wastewater system or our rivers and oceans. Tackling the impact of prescribing will be a key part of meeting the ambition of a net zero NHS Scotland by 2040 at the latest. Together, RCGP Scotland and RPS have held two roundtable events on sustainable prescribing, and in June 2022, released a joint statement calling for a wide range of actions, which was signed by the Academy of Medical Royal Colleges and Faculties in Scotland, the Royal College of Physicians of Edinburgh, the Royal College of Anaesthetists, the College of Radiographers, Royal College of Nursing, Queen's Nursing Institute Scotland and Chartered Society of Physiotherapy. Continuing the work of RPS at the International Forum on Quality and Safety in Healthcare, the event aims to mark an opportunity for health professionals and decision makers alike to join a global movement of sustainability in healthcare, and pledge to continue the important work of cutting the climate impact of medicine use while maintaining the highest level of patient care and safety.

In a recent announcement the Medicines and Healthcare products Regulatory Agency (MHRA) unveiled its strategic approach to artificial intelligence (AI), as it sets out to embrace the transformative potential of AI in healthcare regulation. Building upon the Government's white paper 'A pro-innovation approach to AI regulation', released in 2023, the MHRA outlined five key strategic principles guiding its adoption of AI. These principles encompass safety, security, and robustness; appropriate transparency and explainability; fairness, accountability, and governance; and contestability and redress. A science-led organization, the MHRA was tasked with providing an independent view of its approach to AI in medicine and science, aligning with a government white paper. Recognising its role in UK's goal to be a science and tech leader by 2030, MHRA is tasked to evaluate AI's opportunities and risks across regulatory, public service, and evidence-based decision-making area.

The Department of Health and Social Care (DHSC) has unveiled proposed updates to the NHS Constitution for England, signalling a significant step forward in prioritizing patient privacy, dignity, and safety. At the heart of these reforms lies Martha's Rule, a testament to the power of grassroots advocacy and the enduring legacy of 13-year-old Martha Mills. Martha's Rule, born from the tragic loss of Martha Mills due to a failure in escalating her care, stands as a beacon of hope for future patients and their families. Prompted by Martha's parents' tireless campaign, this rule empowers patients to request intimate care from providers of the same biological sex, ensuring that individual needs are recognized and respected. Additionally, it guarantees the right to a rapid review from an external care team when a patient's condition deteriorates, offering a lifeline in moments of crisis.

The General Pharmaceutical Council's Investigating Committee took decisive action on March 25, 2024, by issuing a warning to Dilsha Kiran Shah, registration number: 2049787, for her conduct as Superintendent Pharmacist of Jhoots Healthcare Ltd. Miss Shah's failure to uphold the Medicines Act 1968, specifically in ensuring the proper management of medicinal products, triggered this warning. The Act mandates supervision in "keeping, preparing, and dispensing medicinal products other than those on a general sale list." Moreover, pharmacies are inspected on five principles - Governance, Staff, Premises, Services including medicines management, and Equipment and facilities to meet the right standards. The alarm was initially raised in August 2021 when a Jhoots Healthcare Ltd pharmacy branch under Miss Shah's supervision operated without a responsible pharmacist. Despite explicit instructions, pharmacy staff were allegedly instructed to proceed without proper supervision, raising grave concerns regarding patient safety.

The Department of Health and Social Care (DHSC) and NHS England last month issued a "safety critical" national patient safety alert, warning about the UK-wide shortage of a life-saving drug used to treat patients with chronic breathing issues. NHS trusts, health authorities, ambulance services, GP practices, private healthcare providers, and community pharmacy contractors were informed that salbutamol 2.5mg and 5mg nebuliser liquid unit dose vials are in short supply, with the latter likely to remain "out of stock" until mid-April 2024. As per the alert, the shortage of the drug resulted from a combination of manufacturing issues, leading to heightened demand for alternative suppliers. It was mentioned that while terbutaline, salbutamol with ipratropium, and ipratropium nebuliser liquids remained available, they could't meet the increased demand.

Long waits for an ambulance or surgery led to the death of 112 people, and nearly 8,000 more people suffered harm while waiting for help in England last year. The data from NHS England, obtained by The Guardian, show that patient deaths arising directly from care delays have risen more than fivefold over the last three years. In 2019, there were 21 patient deaths due to NHS care delays, and 96 people suffered "severe harm" as compared to 152 last year. Adult mental health care was mostly affected with 471 patients experiencing harm due to delays, followed by childbirth care (253), eye problems (221), and trauma and general surgery (207). There has been increase of 97 percent in the overall number of people suffering some degree of harm, from 3,979 in 2019 to 7,856 in 2022.